165 related articles for article (PubMed ID: 31479414)
21. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
22. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.
Stancheva G; Goranova T; Laleva M; Kamenova M; Mitkova A; Velinov N; Poptodorov G; Mitev V; Kaneva R; Gabrovsky N
Biomed Res Int; 2014; 2014():654727. PubMed ID: 24868540
[TBL] [Abstract][Full Text] [Related]
23. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
24. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
25. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
[TBL] [Abstract][Full Text] [Related]
26. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
[TBL] [Abstract][Full Text] [Related]
30. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.
Cai J; Yang P; Zhang C; Zhang W; Liu Y; Bao Z; Liu X; Du W; Wang H; Jiang T; Jiang C
Oncotarget; 2014 May; 5(9):2551-61. PubMed ID: 24810474
[TBL] [Abstract][Full Text] [Related]
31. Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
Das BR; Tangri R; Ahmad F; Roy A; Patole K
Asian Pac J Cancer Prev; 2013; 14(12):7261-4. PubMed ID: 24460285
[TBL] [Abstract][Full Text] [Related]
32. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
33. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
[TBL] [Abstract][Full Text] [Related]
34. R132H Mutation in IDH1 Gene is Associated with Increased Tumor HIF1-Alpha and Serum VEGF Levels in Primary Glioblastoma Multiforme.
Yalaza C; Ak H; Cagli MS; Ozgiray E; Atay S; Aydin HH
Ann Clin Lab Sci; 2017 May; 47(3):362-364. PubMed ID: 28667042
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.
Bujko M; Kober P; Matyja E; Nauman P; Dyttus-Cebulok K; Czeremszyńska B; Bonicki W; Siedlecki JA
Mol Diagn Ther; 2010 Jun; 14(3):163-9. PubMed ID: 20560678
[TBL] [Abstract][Full Text] [Related]
36. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
37. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Ohno M; Narita Y; Miyakita Y; Matsushita Y; Arita H; Yonezawa M; Yoshida A; Fukushima S; Takami H; Ichimura K; Shibui S
Jpn J Clin Oncol; 2016 Jan; 46(1):31-9. PubMed ID: 26603354
[TBL] [Abstract][Full Text] [Related]
38. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
39. Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
Mistry AM; Vnencak-Jones CL; Mobley BC
J Neurooncol; 2018 Jun; 138(2):307-313. PubMed ID: 29423539
[TBL] [Abstract][Full Text] [Related]
40. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.
Mandel JJ; Cachia D; Liu D; Wilson C; Aldape K; Fuller G; de Groot JF
J Neurooncol; 2016 Aug; 129(1):147-54. PubMed ID: 27270908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
